Wilbur Strader
Endocrinology, Diabetes & Metabolism · El Paso, TXNPI 1740283043
Payments from drug & device makers
Across 317 payments — averaging $33.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Novo Nordisk$2K
- Amgen$1K
- Lilly USA, LLC$494
- AstraZeneca$491
- Sanofi-aventis U.S. LLC$420
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$3,00029%
- Food & beverage$7,12068%
- Education$3944%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $3,614 |
| Novo Nordisk | 114 | $1,965 |
| Amgen(2 entities) | 26 | $1,414 |
| Lilly USA, LLC | 19 | $494 |
| AstraZeneca | 20 | $491 |
| Sanofi-aventis U.S. LLC | 27 | $420 |
| Radius Health, Inc. | 11 | $308 |
| Boehringer Ingelheim | 9 | $303 |
| Abbott | 11 | $215 |
| Bayer | 5 | $206 |
| Merck | 10 | $167 |
| Johnson & Johnson | 7 | $167 |
| BETA Bionics, Inc. | 2 | $165 |
| Inspire Medical Systems, Inc. | 1 | $109 |
| Amarin Pharma, Inc. | 5 | $104 |
| Recordati_rare_diseases_inc. | 5 | $68 |
| Corcept Therapeutics | 3 | $51 |
| Arbor Pharmaceuticals, Inc. | 2 | $36 |
| Dexcom, Inc. | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Medtronic(2 entities) | 2 | $29 |
| Shire North American Group Inc | 2 | $28 |
| Insulet Corporation | 1 | $24 |
| IBSA Pharma Inc. | 1 | $22 |
| Mannkind Corporation | 1 | $19 |
| Antares Pharma, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,515 in reported general payments places this provider in the 65th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 18 | $38,882 |
| SynthroidLevothyroxine Sodium | 17 | $2,081 |
| Zolpidem Tartrate | 19 | $210 |
| Rosuvastatin Calcium | 15 | $169 |
| Levothyroxine Sodium | 22 | $147 |
| Temazepam | 14 | $107 |
| Pioglitazone Hcl | 11 | $80 |
| Atorvastatin Calcium | 16 | $80 |
| Alprazolam | 16 | $46 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,965 | $38,88218 claims |
| AbbVieSynthroid | $3,614 | $2,08117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in El Paso
- Sergio RovnerEl Paso$2.9M
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
- Eduardo LunaEdinburg$7.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.